Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Med Intensiva ; 39(9): 552-62, 2015 Dec.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-26183121

RESUMO

In recent years, several safety alerts have questioned or restricted the use of some pharmacological alternatives to allogeneic blood transfusion in established indications. In contrast, there seems to be a promotion of other alternatives, based on blood products and/or antifibrinolytic drugs, which lack a solid scientific basis. The Multidisciplinary Autotransfusion Study Group and the Anemia Working Group España convened a multidisciplinary panel of 23 experts belonging to different healthcare areas in a forum for debate to: 1) analyze the different safety alerts referred to certain transfusion alternatives; 2) study the background leading to such alternatives, the evidence supporting them, and their consequences for everyday clinical practice, and 3) issue a weighted statement on the safety of each questioned transfusion alternative, according to its clinical use. The members of the forum maintained telematics contact for the exchange of information and the distribution of tasks, and a joint meeting was held where the conclusions on each of the items examined were presented and discussed. A first version of the document was drafted, and subjected to 4 rounds of review and updating until consensus was reached (unanimously in most cases). We present the final version of the document, approved by all panel members, and hope it will be useful for our colleagues.


Assuntos
Anemia/terapia , Estado Terminal/terapia , Hemorragia/terapia , Anemia/tratamento farmacológico , Antifibrinolíticos/efeitos adversos , Antifibrinolíticos/uso terapêutico , Aprotinina/efeitos adversos , Aprotinina/uso terapêutico , Fatores de Coagulação Sanguínea/efeitos adversos , Fatores de Coagulação Sanguínea/uso terapêutico , Transfusão de Sangue/normas , Ensaios Clínicos como Assunto , Soluções Cristaloides , Eritropoetina/efeitos adversos , Eritropoetina/uso terapêutico , Hematínicos/efeitos adversos , Hematínicos/uso terapêutico , Humanos , Derivados de Hidroxietil Amido/efeitos adversos , Derivados de Hidroxietil Amido/uso terapêutico , Ferro/efeitos adversos , Ferro/uso terapêutico , Soluções Isotônicas/efeitos adversos , Soluções Isotônicas/uso terapêutico , Metanálise como Assunto , Estudos Observacionais como Assunto , Substitutos do Plasma/efeitos adversos , Substitutos do Plasma/uso terapêutico , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Ácido Tranexâmico/efeitos adversos , Ácido Tranexâmico/uso terapêutico , Reação Transfusional
2.
Med Clin (Barc) ; 115(14): 540-1, 2000 Oct 28.
Artigo em Espanhol | MEDLINE | ID: mdl-11141380

RESUMO

BACKGROUND: We have examined the variation in the promoter region in the gene encoding UGT-1, associated with Gilbert's syndrome, in Spanish population. PATIENTS AND METHOD: Blood DNA was obtained from 100 blood donors. Polymerase chain reaction (PCR) was used to examine the A(TA)nTAA motif in the promoter region of the UGT-1 gene. RESULTS: The frequency of the abnormal 7/7 genotype in Spanish population was 9%. The heterozygous 6/7 genotype was identified in 51% of the subjects. CONCLUSIONS: The frequency of the abnormal allele, similar in different caucasian populations, raise the question whether it would be worthwhile and cost-effective to introduce molecular screening for Gilbert's syndrome in the study of mild, chronic unconjugated hyperbilirubinemia, in the absence of haemolysis or evidence of hepatic injury.


Assuntos
Alelos , Doença de Gilbert/genética , Glucuronosiltransferase/genética , Regiões Promotoras Genéticas/genética , Doadores de Sangue , Genótipo , Humanos , Mutação/genética , Espanha/etnologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa